cyclophosphamide + azacitidine

Cyclophosphamide + azacitidine is an investigational combination therapy consisting of two small molecule chemotherapeutic agents. Cyclophosphamide is a nitrogen mustard alkylating agent that requires hepatic activation and exerts its antineoplastic effects primarily through DNA cross-linking, leading to inhibition of DNA replication and cell death. Azacitidine is a pyrimidine nucleoside analogue with dual mechanisms of action: it incorporates into RNA and DNA, disrupting their function, and inhibits DNA methyltransferase, resulting in hypomethylation of DNA. This can lead to reactivation of silenced genes involved in tumor suppression and apoptosis. The combination has been studied as part of multi-agent regimens for hematologic malignancies such as peripheral T-cell lymphoma (PTCL), acute lymphoblastic leukemia (ALL), myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML). In these settings, the addition of azacitidine may help overcome chemoresistance by altering epigenetic regulation[1][4][7][10].

Brand names

CytoxanVidaza

Other names

cyclophosphamide + azacitidine-The University of Hong Kong-lupus nephritis